q&more
My watch list
my.chemie.de  
Login  
Paradigm shift

Paradigm shift

Setting the course in genetic diagnostics and personalised medicine

Prof. Dr. Theo Dingermann (Johann Wolfgang Goethe-Universität Frankfurt (Main), Institut für Pharmazeutische Biologie)

What  would medicine be without drugs? But are these drugs being used optimally today? Not at all, as we now know thanks to the findings of molecular medicine. Because for  the use of these drugs, it is important to observe  two aspects: the disease and the patient. Only slowly  is it becoming possible to more and more include  patient-relevant information into a treatment decision.

Before a drug is authorized  for use in human beings, it is extensively tested  - initially in the most varied bio­chemical-pharmacological models in test-tubes or in an organ bath, then in diverse animal models and finally on test persons and patients. This tiered approach allows for reliable conclusions regarding the effectiveness and tolerability of the drug. And only when a benefit/risk analysis is clearly in favour of the benefits, will the drug be awarded access to the market via licensing by international or national authorities.

However, these statements are somewhat ambiguous in their details, since they are based on the formation of a more or less projected Gaussian distribution. This is what we have become accustomed to, because there is no alternative. However, were a large enough test population selected, this would show some radical “outliers”. Those affected by such a marginal population can, in some cases, have major problems with such a drug. This is because swings in the direction of “ineffectiveness” are just as possible as swings in the direction of individual overdose during, an in principle, correct application, which can be expressed as intolerance ­to the point of acute toxicity.

With the rapidly increasing demand for security in our society in  recent years, such individual swings, in terms of safety and efficacy, can place a drug itself at risk. An increase in  reports of insufficient efficacy, or side effects, though low in number yet  serious in effect can nowadays quickly lead to the loss of the licence. It is, therefore, in the interest of patients, as well as the pharmaceutical industry, to take measures to make such fluctuations in terms of efficacy and tolerability of a drug predictable and thereby preventable.

The causes of these individual deviations from the norm are differences in the genetic makeup of the patients. These can be such that, due to the possibility of physiological ­“detours”, the properties of a drug are cancelled out. They can also affect the functional units (enzymes and transporters), which naturally modify the active substance or grant  the drug access to the target structure.

Today it often possible, in principle, to recognise these deviations,  respective measures operate under the heading  “stratified medicine”. The consequences, which will result in the use of this technical potential, will amount to a paradigm shift. In due time we will see a change, from the treatment of a disease to the treatment of a patient with a specific genetic makeup.

Many examples have been listed where already today a therapy could be significantly optimised, if  therapy decisions were not only based on disease-related parameters but rather the patient-specific genetic parameters were also included. Diagnostics – and more than ever genetic diagnostics – ­receive  a new quality here: the traditional  terrain of disease-related diagnostic investigation will be supplemented by diagnostics that will reveal whether and how drugs may act on  a certain disease.

These new prospects would make good, existing  therapies in many ways even better - particularly for patients who, based on individual parameters, do not fall within the crown region of a Gaussian distribution of the outcome of  a clinical efficacy study.

First publication: Dingermann, T., q&more, 1.2011.

Facts, background information, dossiers

  • diagnostics
  • medicine
  • drugs
  • personalized medicine
  • genetic diagnostics
  • drug safety

Other articles by these authors

All articles

Why biosimilars and not biogenerics?

Medicines produced using genetic techniques have existed since 2006, called “similar biological medicinal products” or “biosimilars”. Until a year ago, this was a fairly low-profile group (…)

More about Uni Frankfurt am Main

  • News

    How do killer T cells know where danger is coming from?

    How do killer T cells recognise cells in the body that have been infected by viruses? Matter foreign to the body is presented on the surface of these cells as antigens that act as a kind of road sign. A network of accessory proteins – the chaperones – ensure that this sign retains its stabi ... more

    Laboratory study: effect of antibodies against omicron variants BA.1 and BA.2 wears off quickly

    The omicron variants BA.1 and BA.2 of the SARS-CoV-2 virus, which are dominant from about December to April, can undermine the protection against infection offered by vaccinations or survived infections after only three months. This is shown by a study from Frankfurt under the leadership of ... more

    How bacteria adhere to cells: Basis for the development of a new class of antibiotics

    The adhesion of bacteria to host cells is always the first and one of the decisivesteps in the development of infectious diseases. The purpose of this adhesion by infectious pathogens is first to colonize the host organism (i.e., the human body), and then to trigger an infection, which in t ... more

  • q&more articles

    From feast to famine and back – no problem for bacteria

    Bacteria are true survivors. In the course of evolution, they have developed numerous strategies to adapt to rapidly changing, uncertain environmental conditions. Their metabolism is much more sophisticated than that of human beings. Within minutes they can regulate their gene expression an ... more

    Why biosimilars and not biogenerics?

    Medicines produced using genetic techniques have existed since 2006, called “similar biological medicinal products” or “biosimilars”. Until a year ago, this was a fairly low-profile group, even in expert circles. This has all changed now, however, with the recent licensing of the first bios ... more

    Polar and a potential drinking water hazard

    In Germany, drinking water supplies are plentiful and generally of a high quality. Drinking water is in Germany most commonly produced from groundwater (69.6 %), with a further 12.4 % being taken from lakes and dam reservoirs. The proportion of drinking water processed from bank filtration ... more

  • Authors

    Prof. Dr. Claudia Büchel

    Claudia Büchel, born in 1962, studied biology at the University of Mainz, where she also received her doctorate and, in 2001, the qualification to teach plant physiology. After a postdoctoral research period at the Biological Research Centre, Szeged, she worked for four years as a research ... more

    Prof. Dr. Jörg Soppa

    Jörg Soppa, born in 1958, studied biochemistry in Tübingen and then went on to do his doctorate at the Max Planck Institute of Biochemistry in Martinsried near Munich. In 1990 he established his own research group there and held courses at the Institute of Genetics and Microbiology of Munic ... more

    Prof. Dr. Heinfried H. Radeke

    Heinfried H. Radeke studied medicine at the Hannover Medical School (MHH) and received his medical license in 1985. His Ph.D. thesis was recognized as the best research dissertation of 1986. After two years as an assistant physician at the Göttingen University Hospital, he began his career ... more

White paper

Product

Most widely read

  1. Weighing in the US Pharmacopeia
  2. Protective effects of secondary plant compounds in focus
  3. Transfer of aroma compounds into breast milk
  4. Drug substances in the drug product dossier
  5. Food ingredients from sunflowers
  6. Weighty matters for the European Pharmacopoeia
  7. Vitamin D in plants
  8. Lean lab methods and safety in the laboratory
  9. Quality assurance in medical laboratories
  10. How the Avogadro constant was measured for the last time

Topics A-Z

All topics

q&more – the networking platform for quality excellence in lab and process

The q&more concept is to increase the visibility of recent research and innovative solutions, and support the exchange of knowledge. In the broad spectrum of subjects covered, the focus is on achieving maximum quality in highly innovative sectors. As a modern knowledge platform, q&more offers market participants one-of-a-kind networking opportunities. Cutting-edge research is presented by authors of international repute. Attractively presented in a high-quality context, and published in German and English, the original articles introduce new concepts and highlight unconventional solution strategies.

> more about q&more

q&more is supported by:

 

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE